A pituitary adenoma is a usually non-cancerous tumour that develops in the pituitary gland, a small organ responsible for regulating several important hormones. Although many pituitary adenomas grow slowly, they may affect vision, hormone levels, metabolism and overall health.
Treatment depends on the tumour’s size, location, hormone activity, symptoms and previous treatment history. Surgery, medication, observation and radiation therapy may all have a role. For selected patients, Pituitary Adenoma Treatment with CyberKnife S7 may offer a precise, non-invasive treatment option.
What Is a Pituitary Adenoma?
Pituitary adenomas may be classified as functioning or non-functioning tumours. Functioning adenomas produce excess hormones, while non-functioning adenomas may cause symptoms by pressing against nearby structures.
Common symptoms may include:
- Headaches.
- Blurred or reduced peripheral vision.
- Irregular menstrual cycles.
- Unexplained weight gain or weight loss.
- Excessive sweating or fatigue.
- Reduced sexual function.
- Abnormal growth in hands, feet or facial features.
- Hormonal imbalance.
An MRI scan, hormonal evaluation and visual-field testing help doctors assess the tumour. A multidisciplinary team involving endocrinologists, neurosurgeons, radiation oncologists and radiologists may then recommend an individualised treatment plan.
How Does CyberKnife S7 Work?
CyberKnife S7 is a robotic stereotactic radiosurgery system that delivers multiple focused radiation beams to a tumour from different angles. The goal is to damage the tumour cells while limiting radiation exposure to surrounding healthy tissue.
The system uses image guidance and robotic movement to support accurate treatment delivery. According to Valentis Cancer Hospital, treatment may be planned over one to five outpatient sessions, with each session generally lasting between 15 and 40 minutes, depending on the patient’s condition and treatment plan.
Unlike conventional surgery, CyberKnife surgery does not require an incision, general anaesthesia or a hospital stay in many cases. However, the term “CyberKnife surgery” refers to radiosurgery not the physical removal of the tumour. The treatment works gradually, and follow-up MRI scans and hormone tests remain important.
When Can It Be Suitable?
CyberKnife S7 may be considered in carefully selected cases, particularly when:
- The adenoma remains after transsphenoidal surgery.
- The tumour has returned after earlier treatment.
- The tumour is located close to critical structures and additional surgery may carry risks.
- The patient is not a suitable candidate for conventional surgery.
- Medication has not adequately controlled a hormone-secreting adenoma.
- The tumour is sufficiently separated from the optic nerves and optic chiasm for safe radiation planning.
For many patients with a newly diagnosed pituitary adenoma causing pressure symptoms or significant hormonal problems, surgery or medication may be considered first. CyberKnife S7 is not automatically the first-line option for every patient.
Research supports stereotactic radiosurgery as an important option for residual or recurrent pituitary adenomas. In a long-term study of 178 patients with non-functioning pituitary adenomas treated with CyberKnife, progression-free survival was 97.47% at three years, 95.57% at five years and 93.04% at ten years.
Potential Benefits
The possible advantages of CyberKnife S7 include:
- Non-invasive treatment without surgical incision.
- No surgical removal or general anaesthesia in typical cases.
- Precise radiation delivery.
- Outpatient treatment in many patients.
- Short treatment sessions.
- A potentially useful option for residual or recurrent tumours.
- Less disruption to daily activities compared with major surgery.
CyberKnife S7 may be particularly valuable when a tumour is difficult to access surgically or when a patient requires additional treatment after surgery. Valentis Cancer Hospital describes the system as using real-time image guidance and a frameless treatment approach for selected tumours.
Risks and Limitations
Although CyberKnife is non-invasive, it is still a high-precision radiation treatment and may cause side effects. Possible risks include:
- Delayed reduction in tumour size.
- Hormonal deficiencies, also called hypopituitarism.
- The need for long-term hormone replacement.
- Visual complications in selected cases.
- Rare radiation-related effects.
- Continued monitoring for tumour progression or recurrence.
The long-term CyberKnife study reported new-onset hypopituitarism in 16.9% of patients during clinical follow-up. New visual disorders occurred in a smaller proportion of patients, and larger tumour volume was associated with increased visual risk.
Therefore, patients should undergo regular hormonal evaluation, ophthalmic assessment and MRI follow-up after treatment. A published clinical report also highlights the importance of monitoring for hypopituitarism and adrenal insufficiency after CyberKnife radiosurgery.
Pituitary Tumor Treatment Cost in India
The pituitary tumor treatment cost in India varies considerably. The final estimate may depend on:
- Tumour size and location.
- Whether the tumour is functioning or non-functioning.
- Number of CyberKnife sessions required.
- MRI, hormonal and visual evaluations.
- Consultation and treatment-planning charges.
- Requirement for surgery, medication or hormone replacement.
- Hospital facilities and specialist expertise.
Published estimates for CyberKnife treatment in India vary widely, so patients should request a personalised quotation after clinical evaluation. One Valentis Cancer Hospital resource cites an approximate CyberKnife treatment range of ₹2 lakh to ₹5 lakh, while another hospital page gives a broader range of ₹3 lakh to ₹10 lakh. These figures are indicative and should not be treated as a guaranteed price.
Is CyberKnife S7 the Right Choice?
CyberKnife S7 may be a suitable option for selected patients with residual, recurrent or difficult-to-treat pituitary adenomas. However, suitability depends on MRI findings, tumour distance from the optic pathways, hormone activity, previous treatment and overall health.
Patients should consult a multidisciplinary team before deciding on treatment. At Valentis Cancer Hospital, specialists can assess the diagnosis and discuss whether surgery, medication, conventional radiation or CyberKnife S7 is most appropriate.
Choosing a best cancer hospital in India should involve more than technology alone. Patients should consider the experience of the treating team, access to endocrinology and neurosurgery support, treatment-planning quality, follow-up services and transparency regarding costs and possible risks.
CyberKnife S7 can be an effective component of modern Pituitary Adenoma Treatment, but the final decision should always be based on an individual medical evaluation rather than promotional claims or cost alone.
